natgillin/translations-raw huggingface dataset:
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4). 
• Okvara ledvic Terapevtske izkušnje pri bolnikih z okvaro ledvic so omejene (glejte poglavje 4.4).
A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding. 
Farmakodinamična interakcija med klopidogrelom in heparinom je možna in vodi do povečanega tveganja za krvavitev.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to 18.7 [p=0.258]). 
Pri analizi podskupin glede na vključitveni pogoj (miokardni infarkt, ishemična kap in periferna arterijska bolezen/PAD/) je videti najmočnejšo korist (doseganje statistične značilnosti pri p=0,003) pri bolnikih, vključenih zaradi PAD (zlasti pri tistih, ki so doživeli tudi miokardni infarkt) (zmanjšanje RT=23,7 %; IZ: 8,9 do 36,2), in šibkejšo (ni bila pomembno različna od ASA) pri bolnikih s kapjo (zmanjšanje RT=7,3 %; IZ: -5,7 do 18,7 [p=0,258]).
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors. 
Kot pri drugih antitrombotikih, moramo klopidogrel uporabljati previdno pri bolnikih s tveganjem za povečano krvavitev zaradi poškodbe, kirurškega posega ali drugih patoloških stanj in pri bolnikih, ki so na zdravljenju z ASA, heparinom, zaviralci glikoproteina IIb/IIIa ali nesteroidnimi protivnetnimi zdravili (NSAIDs) vključno z zaviralci COX-2.
signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Take special care with Clopidogrel Acino Pharma'). 
To so lahko znaki redkega zmanjšanja števila določenih krvnih celic, - znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike, in/ali zmedenostjo (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Klopidogrel Acino Pharma«).
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking Plavix 75 mg/day. 
Odmerek 0,2 mg/kg je dosegel povprečno 49,3 % zavrtje (agregacija trombocitov povzročena s 5 µM ADP), primerljivo kot pri odraslih ob uporabi zdravila Plavix v odmerku 75 mg/dan.
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, rash erythematous, urticaria, eczema, lichen planus 
Bulozen dermatitis (toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem), angioedem, eritematozen izpuščaj, urtikarija, ekcem, lihen planus
Pharmacogenetics: In patients who are poor CYP2C19 metabolisers, clopidogrel at recommended doses forms less of the active metabolite of clopidogrel has a smaller effect on platelet function. 
Farmakogenetika: Pri bolnikih, ki so slabi metabolizatorji CYP2C19, med uporabo priporočenih odmerkov klopidogrela nastane manj aktivnega presnovka klopidogrela in ima manjši učinek na delovanje trombocitov.
swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
- otekanje ust ali bolezni kože, kot so izpuščaj, srbenje in mehurji na koži.
Blood and the lymphatic system disorders 
Bolezni krvi in limfatičnega sistema
Intracranial bleeding (some cases were reported with fatal outcome), headache, paraesthesia, dizziness 
Intrakranialna krvavitev (opisani so primeri s smrtnim izidom), glavobol, parestezije, omotica
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2 - 2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing. 
Povprečna največja koncentracija nespremenjenega klopidogrela v plazmi (približno 2,2-2,5 ng/ml po enem 75-mg peroralnem odmerku) se je pojavila približno 45 minut po odmerjanju.
Store in the original blister in order to protect from moisture. 
Shranjujte v originalnih pretisnih omotih za zagotovitev zaščite pred vlago.
Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4). 
Peroralni antikoagulanti: sočasna uporaba klopidogrela s peroralnimi antikoagulanti ni priporočljiva, ker lahko poveča intenzivnost krvavitev (glejte poglavje 4.4).
A pharmacodynamic interaction between clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding. 
Farmakodinamična interakcija med klopidogrelom in acetilsalicilno kislino je možna in vodi do povečanega tveganja za krvavitev.
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. 
Nesteroidna protivnetna zdravila (NSAIDs; “Non-Steroidal Anti-Inflammatory Drugs”): v klinični študiji, izvedeni pri zdravih prostovoljcih, je sočasna uporaba klopidogrela in naproksena povečala okultno izgubo krvi iz prebavil.
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis 
Krvavitve v dihalih (hemoptiza, pljučna krvavitev), bronhospazem, intersticijski pnevmonitis
Important information about some of the ingredients of Clopidogrel Acino Pharma: Clopidogrel Acino Pharma contains hydrogenated castor oil which may cause stomach upset or diarrhoea. 
Pomembne informacije o nekaterih sestavinah zdravila Klopidogrel Acino Pharma Zdravilo Klopidogrel Acino Pharma vsebuje hidrogenirano ricinusovo olje, ki lahko povzroči želodčne motnje ali drisko.
Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in the way things taste. 
- Zelo redki neželeni učinki: zlatenica, huda bolečina v trebuhu z ali brez bolečine v hrbtu, zvišana telesna temperatura, težave pri dihanju, ki so včasih povezane s kašljem, splošne alergijske reakcije, oteklina v ustih, mehurji na koži, kožna alergija, vnetje v ustih (stomatitis), znižanje krvnega tlaka, zmedenost, halucinacije, bolečine v sklepih, bolečine v mišicah, motnje okusa.
WHAT CLOPIDOGREL ACINO PHARMA IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO KLOPIDOGREL ACINO PHARMA IN ZA KAJ GA UPORABLJAMO
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia 
Trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, granulocitopenija, anemija
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 2 ‘Take special care with Clopidogrel Acino Pharma'). 
Vendar pa se morate takoj posvetovati s svojim zdravnikom, če ste glede krvavitve v kakršnihkoli dvomih (glejte poglavje 2 »Bodite posebno pozorni pri jemanju zdravila Klopidogrel Acino Pharma«).
Serum sickness, anaphylactoid reactions 
Serumska bolezen, anafilaktoidne reakcije
INFORMATION IN BRAILLE Clopidogrel Acino Pharma 75 mg 
PODATKI V BRAILLOVI PISAVI Klopidogrel Acino Pharma 75 mg
Clopidogrel Acino Pharma contains hydrogenated castor oil which may cause stomach upset and diarrhoea. 
Klopidogrel Acino Pharma vsebuje hidrogenirano ricinusovo olje, ki lahko razdraži želodec in povzroči drisko.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions. 
Vendar pa so bolniki, ki so bili vključeni v klinično preskušanje klopidogrela, prejemali sočasno različna zdravila, vključno z diuretiki, zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACEI), kalcijevimi antagonisti, učinkovinami za zniževanje holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z insulinom), antiepileptičnimi učinkovinami in antagonisti glikoproteina IIb/IIIa, brez dokazov o klinično pomembnih neželenih interakcijah.
• If you are allergic (hypersensitive) to clopidogrel or any of the other ingredients of Clopidogrel Acino Pharma; 
• če ste alergični na (preobčutljivza klopidogrel ali katerokoli sestavino zdravila
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5). 
Sočasno dajanje klopidogrela s peroralnimi antikoagulanti se ne priporoča, ker lahko poveča jakost krvavitev (glejte poglavje 4.5).
As a precautionary measure, breast-feeding should not be continued during treatment with clopidogrel. 
Iz varnostnih razlogov naj se z dojenjem med zdravljenjem z zdravilom ne nadaljuje.
Therefore, concomitant use should be undertaken with caution (see section 4.4). 
Zato moramo k sočasni uporabi pristopiti previdno (glejte poglavje 4.4).
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as besilate). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Vsaka filmsko obložena tableta vsebuje 75 mg klopidogrela v obliki klopidogrelijevega besilata.
Clopidogrel Acino Pharma contains the active ingredient Clopidogrel which belongs to a group of medicines called antiplatelet medicinal products. 
Klopidogrel Acino Pharma vsebuje zdravilno učinkovino klopidogrel, ki spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon. 
Pri zelo visokih odmerkih so pri podganah in pavijanih poročali tudi o slabem želodčnem prenašanju (gastritis, želodčne erozije in/ali bruhanje).
As a precaution concomitant use strong or moderate CYP2C19 inhibitors should be discouraged (see sections 4.4 and 5.2). 
Iz previdnosti naj sočasno ne bi uporabljali močnih ali srednje močnih zaviralcev CYP2C19 (glejte poglavji 4.4 in 5.2).
Clopidogrel Acino Pharma 75 mg film-coated tablets are white to off-white, marbled, round and biconvex. 
Klopidogrel Acino Pharma 75 mg tablete so bele do belkaste, marmorirane, okrogle, bikonveksne filmsko obložene tablete.
Ask your doctor or pharmacist for advice before taking any medicine. 
Posvetujete se z zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo.
Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness. 
- Občasni neželeni učinki: glavobol, razjeda na želodcu, bruhanje, slabost, zaprtost, preveč plinov v želodcu ali črevesju, izpuščaji, srbenje, omotica, občutek mravljinčenja in omrtvelosti.
If you suffer from severe liver disease; 
• če imate hudo jetrno obolenje.
PSURs The PSUR submission schedule should follow the PSUR schedule for the reference product. 
Redna posodobljena poročila o varnosti zdravila (PSUR) PSUR morajo biti predloženi v skladu s časovnim razporedom za predložitev PSUR za referenčno zdravilo.
Gastrointestinal and retroperitoneal haemorrhage with fatal outcome, pancreatitis, colitis (including ulcerative or lymphocytic colitis), stomatitis 
Krvavitev v prebavila in retroperitonealna krvavitev s smrtnim izidom, pankreatitis, kolitis (vključno z ulceroznim ali limfocitnim kolitisom), stomatitis
Other alleles associated with absent or reduced metabolism are less frequent and include CYP2C19*4, *5, *6, *7, and *8. 
Drugi aleli, povezani z odsotno ali zmanjšano presnovo, so redkejši in vključujejo CYP2C19*4, *5, *6, *7 in *8 Bolnik, ki je slab metabolizator, ima dva hipofunkcijska alela, kot je pojasnjeno zgoraj.
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension 
Resne krvavitve, krvavitev operacijske rane, vaskulitis, hipotenzija
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Po večkratnih odmerkih 75 mg klopidogrela na dan, je bila pri osebah s hudo ledvično boleznijo (očistek kreatinina 5 do 15 ml/min) inhibicija z ADP sprožene agregacije trombocitov manjša (25 %) od tiste, opažene pri zdravih osebah.
NAME OF THE MEDICINAL PRODUCT Clopidogrel Acino Pharma 75 mg film-coated tablets 
IME ZDRAVILA Klopidogrel Acino Pharma 75 mg filmsko obložene tablete
Do not use Clopidogrel Acino Pharma after the expiry date which is stated on the carton and on the blister after EXP. 
Zdravila Klopidogrel Acino Pharma ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu po oznaki EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
Keep out of the reach and sight of children. 
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
How to store Clopidogrel Acino Pharma Further information 
Shranjevanje zdravila Klopidogrel Acino Pharma Dodatne informacije
Clopidogrel Acino Pharma 75 mg film-coated tablets Clopidogrel 
Klopidogrel Acino Pharma 75 mg filmsko obložene tablete klopidogrel
What Clopidogrel Acino Pharma looks like and contents of the pack 
Izgled zdravila Klopidogrel Acino Pharma in vsebina pakiranja
Do not take Clopidogrel Acino Pharma: 
Ne jemljite zdravila Klopidogrel Acino Pharma:
You have a condition of hardening of arteries (also known as atherosclerosis), and You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease (disturbed blood flow in arms or legs caused by vascular occlusions) 
Zdravilo Klopidogrel Acino Pharma vam je predpisano za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate stanje otrdelih arterij (znano tudi kot ateroskleroza), in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen (moten krvni pretok v rokah ali nogah, ki ga povzroči zapora žil)
-Very rare side effects: 
- Redki neželeni učinki: vrtoglavica.
Each tablet contains 75 mg of clopidogrel (as besilate). 
Ena tableta vsebuje 75 mg klopidogrela v obliki klopidogrelijevega besilata.
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol and nifedipine. 
Pri sočasni uporabi klopidogrela z atenololom, nifedipinom, ali z obema - atenololom in nifedipinom -niso opazili nobenih klinično pomembnih farmakodinamičnih interakcij.
HOW TO TAKE CLOPIDOGREL ACINO PHARMA 
KAKO JEMATI ZDRAVILO KLOPIDOGREL ACINO PHARMA
Musculoskeletal , connective tissue and bone disorders 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva
Take special care with Clopidogrel Acino Pharma: 
Bodite posebno pozorni pri jemanju zdravila Klopidogrel Acino Pharma:
Ethylcellulose (E462) Titanium dioxide (E 171) 
jedro tablete: makrogol 6000 mikrokristalna celuloza (E460) krospovidon (vrsta A) hidrogenirano ricinusovo olje filmska obloga: makrogol 6000 etilceluloza (E462) titanov dioksid (E171)
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg of clopidogrel (as besilate). 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka filmsko obložena tableta vsebuje 75 mg klopidogrela v obliki klopidogrelijevega besilata.
While you are taking Clopidogrel Acino Pharma: 
Ko jemljete zdravilo Klopidogrel Acino Pharma:
This leaflet was last approved in. 
Navodilo je bilo odobreno
Always take Clopidogrel Acino Pharma exactly as your doctor has told you. 
Pri jemanju zdravila Klopidogrel Acino Pharma natančno upoštevajte zdravnikova navodila.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased 
Preiskave krvavitve, zmanjšano število nevtrofilcev, zmanjšano število trombocitov
Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7. 
Večkratni odmerki po 75 mg na dan tvorijo pomembno zaviranje z ADP sprožene agregacije trombocitov od prvega dne.
Diarrhoea, abdominal pain, indigestion or heartburn. 
driska, bolečina v trebuhu, slaba prebava ali zgaga.
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation Esomeprazole is expected to give a similar interaction with clopidogrel. 
Povprečno zavrtje agregacije trombocitov se je zmanjšalo za 39 % (začetni odmerek) oz. 21 % (vzdrževalni odmerek).
Excipients 
Epistaksa
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Acino Pharma: if you have a risk of bleeding such as a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) a recent serious injury a recent surgery (including dental) a planned surgery (including dental) in the next seven days if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days if you have kidney or liver disease 
• če imate tveganje za krvavitev, kot je: zdravstveno stanje s tveganjem za notranjo krvavitev (kot je rana na želodcu) krvna motnja, zaradi katere ste bolj nagnjeni k notranji krvavitvi (krvavitev v tkivih, organih ali sklepih vašega telesa).
Not applicable 
Način uporabe
NAME OF THE MEDICINAL PRODUCT Clopidogrel Acino Pharma 75 mg film-coated tablets Clopidogrel NAME OF THE MARKETING AUTHORISATION HOLDER Acino Pharma GmbH EXPIRY DATE 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Acino Pharma GmbH
The valid summary of product characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure. 
Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo, ki veljajo, so končne različice, ustvarjene med postopkom koordinacijske skupine.
You might have any of these symptoms and/or conditions. 
Pojavi se lahko katerikoli od teh simptomov in/ali stanj.
The overall response rate was 14.1 %. 
Povprečna stopnja odzivnosti je bila 14,1 %.
From a microbiological point of view, the product should be used immediately. 
Z mikrobiološkega vidika je treba zdravilo uporabiti nemudoma.
Additional medicines: 
Dodatna zdravila:
The results of these analyses of efficacy are summarised in the table below: 
Izsledki teh analiz učinkovitosti so povzeti v spodnji preglednici:
Date of latest renewal: 20 September 2009 
Datum zadnjega podaljšanja: 20. september 2009
This is further supported with data from a clinical study. 
To podpirajo tudi podatki iz klinične študije.
Any diarrhoea requiring hospitalisation (irrespective of grade) or grade 3 or 4 diarrhoea. 
Kakršnakoli diareja, ki potrebuje hospitalizacijo (ne glede na stopnjo) ali diareja stopnje 3 ali 4
* Definition of frequency terms: Very common - ≥ 10%; Common - > 5% and < 10%. 
* Definicija pogostnosti: Zelo pogosto - > 10 %; Pogosto - > 5 % in < 10 %.
Between patient variability in clearance is moderate at 19.3 %. 
Variabilnost med bolniki v očistku je zmerna, 19,3 %.
The pH of the reconstituted solution is between 6.6 and 7.8. 
pH pripravljene raztopine je med 6,6 in 7,8.
Calculate the dose and the number of ALIMTA vials needed. 
Izračunajte odmerek in število potrebnih vial zdravila ALIMTA.
Based on the planned date of your infusion of ALIMTA and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. 
Na podlagi načrtovanega datuma vaše infuzije zdravila ALIMTA in/ali glede na delovanje vaših ledvic vam mora zdravnik svetovati, katera zdravila lahko jemljete in kdaj jih lahko jemljete.
The doctor or hospital pharmacist will work out the dose you need based on your height and weight. 
Zdravnik ali bolnišnični farmacevt bo določil odmerek, ki ga potrebujete, na podlagi vaše telesne višine in mase.
In vitro studies indicate that pemetrexed is approximately 81 % bound to plasma proteins. 
Študije in vitro kažejo, da se pemetreksed približno 81 % veže na plazemske beljakovine.
There are many sorts of NSAIDs with different durations of activity. 
Obstaja veliko vrst NSAID z različnimi trajanji delovanja.
Creatinine clearance decreased** 
Znižan očistek kreatinina**
Fully supplemented patients patients 
Bolniki s popolnim bolniki dopolnjevanjem
Fisher's exact p-value* 
Fisherjeva točna p-vrednost*
It is not known whether pemetrexed is excreted in human milk and adverse reactions on the suckling child cannot be excluded. 
Ni znano, ali se pemetreksed izloča v materino mleko, in neželenih reakcij za dojenčka ne moremo izključiti.
The effect of third space fluid, such as pleural effusion or ascites, on pemetrexed is not fully defined. 
Učinek tekočine tretjega prostora, denimo plevralnega izliva ali ascitesa, na pemetreksed ni popolnoma opredeljen.
Not known: frequency cannot be estimated from the available data Lower limb swelling with pain and redness Increased urine output 
Neznana pogostnost: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov Otekanje spodnjih okončin z bolečino in pordelostjo Povečano izločanje urina
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2°C to 8°C. 
pripravljenega za uporabo, ne uporabimo takoj, je za čase shranjevanja in pogoje pred uporabo odgovoren uporabnik, in naj bi ne presegali 24 ur pri 2 do 8 °C.
Further dilution is required. 
Raztopino moramo še nadalje redčiti.
As a result there is sufficient evidence suggesting a causal relationship between the use of pemetrexed and hyperpigmentation. 
Obstaja torej dovolj dokazov, ki kažejo na vzročno povezavo med uporabo pemetrekseda in hiperpigmentacijo.
Particular attention should be paid to these patients and caution exercised with use of other radiosensitising agents. 
Pri teh bolnikih je potrebna posebna pozornost in previdnost pri uporabi drugih radiosenzitirajočih učinkovin.
Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you. 
Pred začetkom jemanja tega zdravila, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Pharmacotherapeutic group: Folic acid analogues, ATC code: L01BA04 
Farmakoterapevtska skupina: Analogi folne kisline, Oznaka ATC: L01BA04
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. 
Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 September 2004 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 20. september 2004
If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs. 
Če niste prepričani, vprašajte zdravnika ali farmacevta, ali je katero od vaših zdravil NSAID.
Log Rank p-value* 
Log Rank p-vrednost*
Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy. 
Učinkovitost in varnost so merili od časa randomizacije po zaključku terapije prvega izbora (indukcijske terapije).